home / stock / fdmt / fdmt news


FDMT News and Press, 4D Molecular Therapeutics Inc.

Stock Information

Company Name: 4D Molecular Therapeutics Inc.
Stock Symbol: FDMT
Market: NASDAQ
Website: 4dmoleculartherapeutics.com

Menu

FDMT FDMT Quote FDMT Short FDMT News FDMT Articles FDMT Message Board
Get FDMT Alerts

News, Short Squeeze, Breakout and More Instantly...

FDMT - 4D Molecular Therapeutics, Inc. (FDMT) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript

2026-03-06 13:46:01 ET 4D Molecular Therapeutics, Inc. (FDMT) TD Cowen 46th Annual Health Care Conference March 3, 2026 10:30 AM EST... Read the full article on Seeking Alpha For further details see: 4D Molecular Therapeutics, Inc. (FDMT) Presents at TD Cowen 46th Annual Hea...

FDMT - Expected US Company Earnings on Friday, March 6th, 2026

Aptevo Therapeutics Inc. (APVO) is expected to report $-8.09 for Q4 2025 Longeveron Inc. (LGVN) is expected to report $-0.41 for Q4 2025 Genesco Inc. (GCO) is expected to report $3.73 for Q4 2026 Algonquin Power & Utilities Corp. (AQN) is expected to report $0.04 for Q4 2025 N...

FDMT - Expected US Company Earnings on Friday, February 27th, 2026

Sunstone Hotel Investors Inc. (SHO) is expected to report $0.18 for Q4 2025 GT Biopharma Inc. (GTBP) is expected to report $-0.22 for Q4 2025 Global Partners LP representing Limited Partner Interests (GLP) is expected to report $0.6 for Q4 2025 4D Molecular Therapeutics Inc. (FDMT) is...

FDMT - FDMT - Historical Price Movements Surrounding Earnings

2026-02-26 17:38:44 ET 4D Molecular Therapeutics, Inc. (FDMT) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 2.35%. The average open to low on the day of earnings was -4.12%. The averag...

FDMT - FDMT - Historical Earnings Price Analysis

2026-02-26 17:33:44 ET 4D Molecular Therapeutics, Inc. (FDMT) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in FDMT stock price following earnings has averaged ±1.14% , with a median of...

FDMT - 4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD

Enrollment for 4FRONT-1, the first registrational trial for 4D-150 in wet AMD, was completed within an approximately 11-month period, ahead of initial projections  4FRONT-1 overenrolled and expected to exceed 500 patients randomized, reflecting strong interest from investigators and patie...

FDMT - 4D Molecular Therapeutics, Inc. (FDMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-14 13:35:58 ET 4D Molecular Therapeutics, Inc. (FDMT) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 10:30 AM EST... Read the full article on Seeking Alpha For further details see: 4D Molecular Therapeutics, Inc. (FDMT) Presents at 44th Annual J.P. Mo...

FDMT - 4DMT Provides Company Update and Anticipated Development Milestones for 2026

Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, with 381 patients randomized or approved to randomize as of January 6, 2026 4D-150 PRISM wet AMD 2-year Phase 2b data expected mid-2026 4D-150 DME ...

FDMT - 4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop

2025-12-19 09:00:00 ET Investment Overview - Update Since My Last Note On 4D-150 The last time I updated on the Emeryville, California-based genetic medicine specialist 4D Molecular Therapeutics ( FDMT ) it was early October 2024, and I made a bull case for the company's sto...

FDMT - 4D Molecular falls after early-stage trial data for cystic fibrosis therapy

2025-12-17 14:02:38 ET More on 4D Molecular Therapeutics 4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential Transcript 4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AER...

Next 10